Shorter treatment for drug-resistant TB brings new hope to SA


The period for the treatment for drug-resistant tuberculosis (TB) in South Africa can potentially be slashed by two-thirds – from the usual 18 months to six – based on the results of a recent study.
The study, which was conducted in South Africa, Russia, Georgia and Moldova, titled High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid, was presented virtually during the International AIDS Society conference on HIV Science on Wednesday. Results show a high success rate in terms of treating drug-resistant TB in a short period of time.
Speaking to Health-e News, after the presentation, Francesca Conradie, a researcher from the Wits University in South Africa, said the results from the study will be crucial in the treatment of the drug-resistant variant of the disease, and it will also play a key role in cutting costs of treating the highly-resistant illness.
.@WitsUniversity’s Francesca Conradie 🇿🇦 is presenting on the high rate of successful outcomes treating highly resistant #TB in the ZeNix study at the #IAS2021 Track B late-breaker session. pic.twitter.com/3URNXjCV9g
— IAS Conference on HIV Science (Inactive account) (@IAS_conference) July 21, 2021
“At the moment, if you are not treated with this group of medicine, you are bound to be treated for 18 months. We have reduced the treatment by two-thirds and that is very significant, as the cost of TB to an individual is very high,” said Conradie.
Randomised
Patients involved in the ZeNix trial were treated for six months with bedaquiline (200mg daily for eight weeks, followed by 100mg daily for 18 weeks), pretomanid (200mg daily) and were equally randomised and dose-blinded with daily linezolid starting at 1 200mg for six months.
According to Conradie, clinical, laboratory and sputum liquid culture evaluations were performed at baseline, weekly for eight weeks and then every two to four weeks through the end of treatment monthly for three months, and at the primary endpoint six months after completion of treatment.
The World Health Organisation (WHO) noted that people with drug-resistant TB face significant economic and social costs and only one in three access quality care.
However, Conradie was hopeful that the results of the ZeNix study will become handy to empower drug-resistant TB patients as they will no longer have to undertake lengthy treatment.
“It means taking fewer pills and remember 50% of the patients we treat for TB also have HIV, so they also take pills for that. The fewer pills one has to take the better, as there will be fewer side-effects, as demonstrated by the study,” said Conradie.
One hundred and eighty-one participants with highly-resistant TB were enrolled in the trial, including 36 (19.9%) who were HIV positive. The result was a high success rate at the primary endpoint.
Efficacy maintained
“What is remarkable about this study is that the efficacy was maintained, as nine out of 10 patients were TB free six months after finishing their treatment. We also found a decreasing rate of side-effects,” she said.
The ZeNix study trial conforms to the high relapse-free cure rate for the bedaquiline, pretomanid and linezolid (BPaL) regimen in highly resistant TB and suggests that reduced doses and/or shorter durations of linezolid than 1 200mg for six months have similar efficacy and improved safety.
Though the study has not been fully completed, as patients who were enrolled in the trial will still be monitored for a few months, Conradie was hopeful that the recommendations from the research will soon be applied in South Africa.
“The study hasn’t fully been completed because what we do with TB is that we watch/monitor our patients for 18 months after they have finished treatment. What I presented today were the results of the first six months after treatment,” she said.
“But if we look at how TB works in general, if the treatment is going to fail it will fail in the first six months. So now we are convinced that we will not get any more problems or relapse as we have already achieved the primary endpoint of the study.”
Conradie added that the researchers did not experience any barriers while conducting the study as everything ran smoothly.
“In South Africa, we adopt new treatments faster than anybody else. We were the first country to use bedaquiline, which is a lifesaver. The research team is very happy with the findings. The procurement is great, we are able to observe our patients even when they are not on clinical trial anymore, so there are no barriers.” – Health-e News
Author
Republish this article

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Shorter treatment for drug-resistant TB brings new hope to SA
by NdivhuwoMukwevho, Health-e News
July 23, 2021
MOST READ
Lack of ambulance forces woman to give birth near hospital gate
US aid Freeze: Call for urgent plan and increased budget for health
Kindness costs: The hidden sacrifices nurses make for patients with TB
US funding freeze disrupts HIV, TB, and GBV support services
EDITOR'S PICKS
Related

Activists say energy department lacks political will to tackle climate change



Activists say energy department lacks political will to tackle climate change

